FdaApplication
NDA 217389
Identifiers
- fda_app_no: NDA217389
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME LLC |
| application_type | NDA |
| approval_date | 2024-06-26 |
Revenue by product
OHTUVAYRE
| Period | Revenue |
|---|---|
| Q2 2026 | $204.0M |
| Q1 2026 | $131.0M |
| Q2 2025 | $0.0M |
| Q1 2025 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OHTUVAYRE | ENSIFENTRINE | 3MG/2.5ML | SUSPENSION;INHALATION |
1 product